U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H26F3N3OS.2ClH
Molecular Weight 510.443
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FLUPHENAZINE HYDROCHLORIDE

SMILES

Cl.Cl.OCCN1CCN(CCCN2C3=C(SC4=C2C=C(C=C4)C(F)(F)F)C=CC=C3)CC1

InChI

InChIKey=MBHNWCYEGXQEIT-UHFFFAOYSA-N
InChI=1S/C22H26F3N3OS.2ClH/c23-22(24,25)17-6-7-21-19(16-17)28(18-4-1-2-5-20(18)30-21)9-3-8-26-10-12-27(13-11-26)14-15-29;;/h1-2,4-7,16,29H,3,8-15H2;2*1H

HIDE SMILES / InChI
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C22H26F3N3OS
Molecular Weight 437.522
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including

Fluphenazine is a trifluoro-methyl phenothiazine derivative intended for the management of schizophrenia and other psychotic disorders. Fluphenazine has not been shown effective in the management of behaviorial complications in patients with mental retardation. Fluphenazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.

CNS Activity

Originator

Squibb von Heyden
7
Curator's Comment: Introduced in 1959

Approval Year

1959
137
Targets

Targets

Primary TargetPharmacologyConditionPotency
Substrate
656
Antagonist
2760
Inverse Agonist
79
 1.412 µM [EC50]
Antagonist
2760
Antagonist
2760
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8360
FLUPHENAZINE DECANOATE

Approved Use

Fluphenazine Decanoate Injection is a long­acting parenteral antipsychotic drug intended for use in the management of patients requiring prolonged parenteral neuroleptic therapy (e.g., chronic schizophrenics).

Launch Date

5.5313282E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2.3 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/8911886
12 mg single, oral
dose: 12 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FLUPHENAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
261 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/8911886
2.5 mg 3 times / 3 days multiple, intravenous
dose: 2.5 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
FLUPHENAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
0.52 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/2313572
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FLUPHENAZINE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
6.92 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/2313572
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FLUPHENAZINE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
14.4 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/8911886
12 mg single, oral
dose: 12 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FLUPHENAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
12.3 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/8911886
2.5 mg 3 times / 3 days multiple, intravenous
dose: 2.5 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
FLUPHENAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
13 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/2313572
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FLUPHENAZINE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
0.6%
EXPERIMENT
https://www.agilent.com/cs/library/applications/5991-2497EN.pdf
FLUPHENAZINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
21 mg 1 times / day multiple, intramuscular (max)
Recommended
Dose: 21 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 21 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/14751428
Page: p.315
unhealthy, 35.4+/-10.4
n = 30
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 35.4+/-10.4
Sex: M+F
Population Size: 30
Sources:
https://pubmed.ncbi.nlm.nih.gov/14751428
Page: p.315
Disc. AE: Akathisia, Dyskinesia...
AEs leading to
discontinuation/dose reduction:
Akathisia (3.3%)
Dyskinesia (3.3%)
Hypertonia (3.3%)
Stupor (3.3%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/14751428
Page: p.315
250 mg 1 times / week multiple, intramuscular
Highest studied dose
Dose: 250 mg, 1 times / week
Route: intramuscular
Route: multiple
Dose: 250 mg, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/11760
Page: p.1438
unhealthy, 44
n = 25
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 44
Sex: M+F
Population Size: 25
Sources:
https://pubmed.ncbi.nlm.nih.gov/11760
Page: p.1438
Sources:
https://pubmed.ncbi.nlm.nih.gov/11760
Page: p.1438
100 mg single, intramuscular|subcutaneous
Recommended
Dose: 100 mg
Route: intramuscular|subcutaneous
Route: single
Dose: 100 mg
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1967dc24-f2a5-4095-baa9-a9d1c5410311&type=display
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1967dc24-f2a5-4095-baa9-a9d1c5410311&type=display
Disc. AE: Tardive dyskinesia, Neuroleptic malignant syndrome...
AEs leading to
discontinuation/dose reduction:
Tardive dyskinesia
Neuroleptic malignant syndrome
Fall
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1967dc24-f2a5-4095-baa9-a9d1c5410311&type=display
AEs

AEs

AESignificanceDosePopulation
Akathisia 3.3%
Disc. AE
21 mg 1 times / day multiple, intramuscular (max)
Recommended
Dose: 21 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 21 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/14751428
Page: p.315
unhealthy, 35.4+/-10.4
n = 30
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 35.4+/-10.4
Sex: M+F
Population Size: 30
Sources:
https://pubmed.ncbi.nlm.nih.gov/14751428
Page: p.315
Dyskinesia 3.3%
Disc. AE
21 mg 1 times / day multiple, intramuscular (max)
Recommended
Dose: 21 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 21 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/14751428
Page: p.315
unhealthy, 35.4+/-10.4
n = 30
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 35.4+/-10.4
Sex: M+F
Population Size: 30
Sources:
https://pubmed.ncbi.nlm.nih.gov/14751428
Page: p.315
Hypertonia 3.3%
Disc. AE
21 mg 1 times / day multiple, intramuscular (max)
Recommended
Dose: 21 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 21 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/14751428
Page: p.315
unhealthy, 35.4+/-10.4
n = 30
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 35.4+/-10.4
Sex: M+F
Population Size: 30
Sources:
https://pubmed.ncbi.nlm.nih.gov/14751428
Page: p.315
Stupor 3.3%
Disc. AE
21 mg 1 times / day multiple, intramuscular (max)
Recommended
Dose: 21 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 21 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/14751428
Page: p.315
unhealthy, 35.4+/-10.4
n = 30
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 35.4+/-10.4
Sex: M+F
Population Size: 30
Sources:
https://pubmed.ncbi.nlm.nih.gov/14751428
Page: p.315
Fall Disc. AE
100 mg single, intramuscular|subcutaneous
Recommended
Dose: 100 mg
Route: intramuscular|subcutaneous
Route: single
Dose: 100 mg
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1967dc24-f2a5-4095-baa9-a9d1c5410311&type=display
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1967dc24-f2a5-4095-baa9-a9d1c5410311&type=display
Neuroleptic malignant syndrome Disc. AE
100 mg single, intramuscular|subcutaneous
Recommended
Dose: 100 mg
Route: intramuscular|subcutaneous
Route: single
Dose: 100 mg
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1967dc24-f2a5-4095-baa9-a9d1c5410311&type=display
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1967dc24-f2a5-4095-baa9-a9d1c5410311&type=display
Tardive dyskinesia Disc. AE
100 mg single, intramuscular|subcutaneous
Recommended
Dose: 100 mg
Route: intramuscular|subcutaneous
Route: single
Dose: 100 mg
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1967dc24-f2a5-4095-baa9-a9d1c5410311&type=display
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1967dc24-f2a5-4095-baa9-a9d1c5410311&type=display
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1709

inhibitor
1579
inhibitor
1752
substrate
1193

inhibitor
1837
inhibitor
1599

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1509
CYP2C19
985
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
1673
 moderate [Ki 40.2 uM]
CYP2C9
1803
 weak [IC50 398.1 uM]
CYP3A4
1909
 weak [IC50 441.2 uM]
CYP2D6
1875
 yes [Ki 9.4 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP2C19
985
 yes
CYP2D6
1193
 yes
CYP3A4
1709
 yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1632
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:5123
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5123
ChemicalBook
CB7107784
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7107784
MolPort
MolPort-001-727-938
https://www.molport.com/shop/molecule-link/MolPort-001-727-938
ZINC
ZINC000019203912
http://zinc15.docking.org/substances/ZINC000019203912
eMolecules
732810
https://www.emolecules.com/cgi-bin/more?vid=732810
PubMed

PubMed

TitleDatePubMed
Dystonic reactions to phenothiazine derivatives.
1966 Oct
Treatment of resistant schizophrenics with extreme high dosage fluphenazine hydrochloride.
1970 Sep-Oct
Side effects of parenteral long-acting phenothiazines.
1972 Jan 22
Maintenance treatment of schizophrenia with long-acting fluphenazine.
1974 Aug
Phenothiazine-induced decompensation.
1974 Jan
Dystonic reaction to high dose propranolol.
1977 Oct 29
Neuroleptics related to butaclamol. An investigation of the effects of chlorine substituents on the aromatic rings.
1978 Dec
High vs standard dosage fluphenazine HCL in acute schizophrenia.
1978 Nov
Phenothiazine-induced dystonic reaction while swimming.
1978 Oct 21
The influence of alpha-adrenergic drugs on catalepsy induced by haloperidol or fluphenazine in rats.
1978 Sep-Oct
Sleep disturbance associated with fluphenazine HCl: a case report.
1979 Jul
Benztropine prophylaxis of dystonic reactions.
1979 Mar 28
Delirium associated with combined fluphenazine-clonidine therapy.
1979 May
behavior of rats and mice administered active metabolites of fluphenazine, 7-hydroxy-fluphenazine and fluphenazine-sulfoxide.
1980 Nov
Neuroleptic-induced acute dyskinesias in rhesus monkeys.
1981
Intrauterine effect of phenothiazines.
1981 Apr 18
Neuroleptic-induced seizures. An in vitro technique for assessing relative risk.
1982 Feb
Sexual dysfunction in women using major tranquilizers.
1982 Sep
A case of neuroleptic malignant syndrome successfully treated with amantadine.
1982 Sep
Occurrence of neuroleptic malignant syndrome in a narcoleptic patient.
1983 Jun
Neuroleptic malignant syndrome.
1984 Jan 7
Sigma opiates and certain antipsychotic drugs mutually inhibit (+)-[3H] SKF 10,047 and [3H]haloperidol binding in guinea pig brain membranes.
1984 Sep
[Catatonia due to fluphenazine].
1986 Apr 1
Drug-induced dystonia in young and elderly patients.
1988 Jul
Manic syndrome associated with zidovudine treatment.
1988 Jun 17
Prolonged fever without extrapyramidal symptoms during neuroleptic treatment.
1989 Jun
Behavioral and electroencephalographic effects of a depot type neuroleptic fluphenazine decanoate, in rats.
1989 Nov
Propranolol withdrawal in psychosis.
1990 Apr
Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment.
1990 Aug
Affective disorder following use of phenylpropanolamine.
1990 Mar
Actions of ORG 5222 as a novel psychotropic agent.
1990 Mar
Blockade of both D-1 and D-2 dopamine receptors may induce catalepsy in mice.
1991
Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
1991 Apr 18
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors.
1994 Mar
Some behavioral effects of CNQX AND NBQX, AMPA receptor antagonists.
1995 Jul-Aug
Fluphenazine plasma levels, dosage, efficacy, and side effects.
1995 May
Some central effects of GYKI 52466, a non-competitive AMPA receptor antagonist.
1995 Nov-Dec
Roxindole, a potential antidepressant. I. Effect on the dopamine system.
1996
Tardive dyskinesia induced by risperidone?
1996 Jun
[Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations].
2006 Jun
Hybrid approach for the design of highly affine and selective dopamine D(3) receptor ligands using privileged scaffolds of biogenic amine GPCR ligands.
2007 Dec 1
Neuroleptic-induced dysphagia: case report and literature review.
2007 Jan
In silico prediction of pregnane X receptor activators by machine learning approaches.
2007 Jan
Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs.
2007 Jul 17
Chronic treatment with fluphenazine alters parameters of oxidative stress in liver and kidney of rats.
2009 Jul
A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle.
2010 Feb 23
An insight into the sialotranscriptome of the brown dog tick, Rhipicephalus sanguineus.
2010 Jul 22
[A case of drug-induced syndrome of inappropriate secretion of antidiuretic hormone].
2010 Jul-Aug
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
Antitubercular pharmacodynamics of phenothiazines.
2013 Apr
Patents

Patents

JP2007525670A
147

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Fluphenazine Decanoate Injection may be given IM or SC
For most patients, a dose of 12.5 to 25 mg (0.5 to 1 mL) may be given to initiate therapy.
Route of Administration: Intramuscular
In Vitro Use Guide
30uM Fluphenazine inhibited the high-threshold Ca2 channel current in rat sympathetic neurons (blocking by 66%).
Substance Class Chemical
Created
by admin
on Thu Jul 06 00:41:37 UTC 2023
Edited
by admin
on Thu Jul 06 00:41:37 UTC 2023
Record UNII
ZOU145W1XL
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FLUPHENAZINE HYDROCHLORIDE
JAN   MART.   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
Common Name English
ANATENSOL
Common Name English
1-PIPERAZINEETHANOL, 4-(3-(2-(TRIFLUOROMETHYL)-10H-PHENOTHIAZIN-10-YL)PROPYL)-, DIHYDROCHLORIDE
Common Name English
FLUPHENAZINE HCL
Common Name English
FLUPHENAZINE HYDROCHLORIDE [VANDF]
Common Name English
FLUPHENAZINE HYDROCHLORIDE [USP IMPURITY]
Common Name English
SQUIBB 4918
Code English
FLUPHENAZINE DIHYDROCHLORIDE [MI]
Common Name English
DAPOTUM
Common Name English
FLUPHENAZINI HYDROCHLORIDUM [WHO-IP LATIN]
Common Name English
FLUPHENAZINE HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
PERMITIL
Brand Name English
FLUPHENAZINE DIHYDROCHLORIDE
EP   MI  
Common Name English
NSC-179197
Code English
Fluphenazine hydrochloride [WHO-DD]
Common Name English
FLUPHENAZINE HYDROCHLORIDE [MART.]
Common Name English
FLUPHENAZINE HYDROCHLORIDE [JAN]
Common Name English
4-[3-[2-(Trifluoromethyl)phenothiazin-10-yl]propyl]-1-piperazineethanol dihydrochloride
Systematic Name English
FLUPHENAZINE HYDROCHLORIDE [USP-RS]
Common Name English
PROLIXIN
Brand Name English
FLUPHENAZINE HYDROCHLORIDE [WHO-IP]
Common Name English
FLUPHENAZINE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29710
Created by admin on Thu Jul 06 00:41:37 UTC 2023 , Edited by admin on Thu Jul 06 00:41:37 UTC 2023
Code System Code Type Description
ECHA (EC/EINECS)
205-674-1
Created by admin on Thu Jul 06 00:41:37 UTC 2023 , Edited by admin on Thu Jul 06 00:41:37 UTC 2023
PRIMARY
EVMPD
SUB02232MIG
Created by admin on Thu Jul 06 00:41:37 UTC 2023 , Edited by admin on Thu Jul 06 00:41:37 UTC 2023
PRIMARY
DRUG BANK
DBSALT000288
Created by admin on Thu Jul 06 00:41:37 UTC 2023 , Edited by admin on Thu Jul 06 00:41:37 UTC 2023
PRIMARY
NSC
179197
Created by admin on Thu Jul 06 00:41:37 UTC 2023 , Edited by admin on Thu Jul 06 00:41:37 UTC 2023
PRIMARY
PUBCHEM
67356
Created by admin on Thu Jul 06 00:41:37 UTC 2023 , Edited by admin on Thu Jul 06 00:41:37 UTC 2023
PRIMARY
RS_ITEM_NUM
1282004
Created by admin on Thu Jul 06 00:41:37 UTC 2023 , Edited by admin on Thu Jul 06 00:41:37 UTC 2023
PRIMARY
MERCK INDEX
M5490
Created by admin on Thu Jul 06 00:41:37 UTC 2023 , Edited by admin on Thu Jul 06 00:41:37 UTC 2023
PRIMARY Merck Index
NCI_THESAURUS
C47995
Created by admin on Thu Jul 06 00:41:37 UTC 2023 , Edited by admin on Thu Jul 06 00:41:37 UTC 2023
PRIMARY
CAS
146-56-5
Created by admin on Thu Jul 06 00:41:37 UTC 2023 , Edited by admin on Thu Jul 06 00:41:37 UTC 2023
PRIMARY
DAILYMED
ZOU145W1XL
Created by admin on Thu Jul 06 00:41:37 UTC 2023 , Edited by admin on Thu Jul 06 00:41:37 UTC 2023
PRIMARY
ChEMBL
CHEMBL726
Created by admin on Thu Jul 06 00:41:37 UTC 2023 , Edited by admin on Thu Jul 06 00:41:37 UTC 2023
PRIMARY
EPA CompTox
DTXSID00892922
Created by admin on Thu Jul 06 00:41:37 UTC 2023 , Edited by admin on Thu Jul 06 00:41:37 UTC 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
FLUPHENAZINE HYDROCHLORIDE
Created by admin on Thu Jul 06 00:41:37 UTC 2023 , Edited by admin on Thu Jul 06 00:41:37 UTC 2023
PRIMARY Description: A white or almost white, crystalline powder; odourless. Solubility: Soluble in 10 parts of water; sparingly soluble in ethanol (~750 g/l) TS; practically insoluble in ether R. Category: Neuroleptic.Storage: Fluphenazine hydrochloride should be kept in a well-closed container, protected from light. Additional information: Even in the absence of light, Fluphenazine hydrochloride is gradually degraded on exposure to a humid atmosphere, the decomposition being faster at higher temperatures. Definition: Fluphenazine hydrochloride contains not less than 98.5% and not more than 101.5% of C22H26F3N3OS,2HCl, calculated with reference to the dried substance.
FDA UNII
ZOU145W1XL
Created by admin on Thu Jul 06 00:41:37 UTC 2023 , Edited by admin on Thu Jul 06 00:41:37 UTC 2023
PRIMARY
RXCUI
203207
Created by admin on Thu Jul 06 00:41:37 UTC 2023 , Edited by admin on Thu Jul 06 00:41:37 UTC 2023
PRIMARY RxNorm
SMS_ID
100000090436
Created by admin on Thu Jul 06 00:41:37 UTC 2023 , Edited by admin on Thu Jul 06 00:41:37 UTC 2023
PRIMARY
Related Record Type Details
Structure of FLUPHENAZINE HYDROCHLORIDE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
Structure of FLUPHENAZINE
PARENT -> SALT/SOLVATE
Structure of FLUPHENAZINE HYDROCHLORIDE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
Related Record Type Details
Structure of 2-(4-(3-(2',8-BIS(TRIFLUOROMETHYL)-10H-3,10'-BIPHENOTHIAZIN-10-YL)PROPYL)PIPERAZIN-1-YL)ETHANOL
IMPURITY -> PARENT
at 260 nm
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 2-(4-(3-(7-(3-(4-(2-HYDROXYETHYL)PIPERAZIN-1-YL)PROPOXY)-2-(TRIFLUOROMETHYL)-10H-PHENOTHIAZIN-10-YL)PROPYL)PIPERAZIN-1-YL)ETHANOL
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of FLUPHENAZINE SULFOXIDE
IMPURITY -> PARENT
274 nm
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 10,10'-(PIPERAZINE-1,4-DIYLBIS(PROPANE-3,1-DIYL))BIS(2-(TRIFLUOROMETHYL)-10H-PHENOTHIAZINE)
IMPURITY -> PARENT
at 260 nm
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of FLUPHENAZINE S,S-DIOXIDE
IMPURITY -> PARENT
274 nm
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of PERPHENAZINE
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of N-DESMETHYL TRIFLUOPERAZINE
IMPURITY -> PARENT
Related Record Type Details
Structure of FLUPHENAZINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966